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Objectives: Upon completion of this article, the reader will
be able to discuss the role of anticoagulants in the interven-
tional radiology population, as well as differentiate between
the most commonly used agents in these drug classes.
Anticoagulation is the cornerstone of acute venous
thromboembolism (VTE) treatment including pulmonary
embolism (PE) and deep venous thrombosis (DVT).1,2 The
goal of anticoagulation is to prevent thrombus extension and
development of new thrombi. Conventional treatment con-
sists of parenteral treatment, usually low-molecular-weight
heparin (LMWH), for at least 5 days.1 Vitamin K antagonists
(VKAs) are started parallel to the parenteral treatment which
is continued until the international normalized ratio (INR)
has reached a therapeutic range (between 2.0 and 3.0) on 2
consecutive days (Class I, Level B recommendation).1 The
widespread introduction of direct oral anticoagulants
(DOACs) in stable VTE patients has revolutionized their
management. The latest guidelines recommend DOACs as
the preferred standard anticoagulation.2 Indeed, DOACs have
several advantages: no requirement for routine monitoring,
minimal food and drug interaction, and fixed dose adminis-
tration. Four DOACs are available for VTE treatment—rivar-











Abstract Anticoagulant therapy is the cornerstone of therapeutic management in acute venous
thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombo-
sis. Direct oral anticoagulants (DOACs) have become the standard of care because of
their good safety profile and ease of use in clinical practice. Indeed, phase 3 randomized
trials (AMPLIFY, EINSTEIN, RECOVER, and HOKUSAI studies) showed that DOACs
provided a similar efficacy and a better safety than conventional treatment with
parenteral heparin with overlapping loading dose of vitamin K antagonists in acute VTE
therapeutic management. The results of published data from real-world registries
confirm the safety and efficacy of DOACs demonstrated in the phase 3 trials.
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and dabigatran (direct thrombin [factor II] inhibitor). Effi-
cacy and safety of DOACS in acute PE have been studied in
several large phase 3 randomized trial programs: RE-
COVER,3 HOKUSAI,4 AMPLIFY,5 and EINSTEIN.6,7 Moreover,
DOACs have been studied for the long-term management of
acute VTE as well: RE-SONATE,8 RE-MEDY,8 EINSTEIN
EXTENSION,6 EINSTEIN CHOICE,9 AMPLIFY EXTENSION,10
and HOKUSAI EXTENSION.11
In this clinical review,we aim (1) to summarize the results
of the phase 3 trials assessing DOACs in VTE and (2) to
describe the results of real-world registries assessing the
safety and efficacy of DOACs.
Phase 3 Trials of Acute VTE: Efficacy and
Safety
The efficacy and safety of DOACs have been compared with
VKA in 27,096 patients with VTE, of whom 11,612 were
diagnosed with acute PE, in four clinical trial programs.3–7,12
The results of these studies assessing DOACs in PE are sum-
marized in ►Table 1. The primary efficacy endpoint of these
trials was recurrent VTE or VTE-related death. The primary
safety outcome was the composite of major and clinically
relevant non-major (CRNM) bleeding according to the Inter-
national Society on Thrombosis Haemostasis (ISTH) criteria.13
In the double-blind, noninferiority RE-COVER I (efficacy and
safety of dabigatran compared with warfarin for 6 months
treatment of acute symptomatic venous thromboembolism)
study, dabigatran after a mean parenteral anticoagulation
duration of 10 days was compared with VKA in 2,539 patients
with VTE.12 Both study arms were equally efficacious for the
incidence of recurrent VTE or VTE-related death (2.4 vs. 2.1%,
hazard ratio [HR]:1.10,95%confidence interval [CI]: 0.65–1.84).
Major bleeding incidences were similar (1.6 vs. 1.9%, HR: 0.82,
95% CI: 0.45–1.48) between the study arms, whereas the
combined safety criteria including major or CRNM bleeding
was significantly reduced in the dabigatran arm (5.6 vs. 8.8%,
HR: 0.63, 95% CI: 0.47–0.84). RECOVER II3 study design was
essentially identical to RECOVER I12 study design. RECOVER II3
study including 2,589 patients with acute VTE confirmed the
results of RECOVER I study12 with noninferiority of dabigatran
towarfarin in the prevention of recurrent VTE and with super-
iorityofdabigatranforCRNMandforanybleeding. In thepooled
analysis of these two studies, HRs for recurrent VTE, major
bleeding, and any bleeding for dabigatran versus warfarinwere
1.09 (95%CI: 0.76–1.57), 0.73 (95%CI: 0.48–1.11), and0.70 (95%
CI: 0.61–0.79), respectively.
In the open-label and noninferiority EINSTEIN studies,
rivaroxaban was compared with conventional treatment by
heparin and warfarin in 8,281 patients with VTE, including
4,855 patients with acute PE.6,7 The incidence of recurrent
VTE in EINSTEIN PE study was noninferior in rivaroxaban
arm compared with enoxaparin/VKA arm (2.1 vs. 1.8%, HR:
1.12, 95% CI: 0.75–1.68).7 The rate of major bleeding was
significantly lower in rivaroxaban group compared with
warfarin group (HR: 0.49, 95% CI: 0.31–0.79), whereas the
incidence of clinical relevant bleeding was similar in both
treatment arms (10.3 vs. 11.4%, HR: 0.90, 95% CI: 0.76–1.07).
A total of 5,395 patients with VTE were included in the
AMPLIFY study of whom 1,836 had PE. Apixaban was found
to be noninferior to standard anticoagulation therapy for the
incidence of VTE or VTE-related deaths (2.3 vs. 2.7%, HR: 0.84,
95% CI: 0.60–1.18) and was associated with a significant
reduction of the incidence of major bleeding (0.6 vs. 1.8%,
RR ¼ 0.31, 95% CI: 0.17–0.55; p < 0.001).5
In the double-blind Hokusai-VTE study, standard antic-
oagulation therapy was compared with edoxaban after a
short course of heparin in 8,292 patients with VTE, of whom
3,319 were diagnosed with acute PE.4 The incidence of
recurrent VTE or VTE-related deaths following 12 months
of treatment was similar in both arms (3.5 vs. 3.2%, HR: 0.89,
95% CI: 0.70–1.13) and the incidence of clinically relevant
bleeding events was significantly lower in the edoxaban
group with 8.5 versus 10.3%, respectively (HR ¼ 0.81, 95%
CI: 0.71–0.94). The rates ofmajor bleeding in both armswere
similar (1.4 vs. 1.6%, HR: 0.84, 95% CI: 0.59–1.21).
A meta-analysis pooling the data of these phase 3 trials
comparing DOACs with VKAs showed that relative risks (RRs)
for recurrent VTE, fatal PE, and overall mortality for DOACs
versusVKAswere0.88 (95%CI: 0.74–1.05,p ¼ 0.46), 1.02 (95%
CI: 0.39–5.96, p ¼ 0.71), and 0.97 (95% CI: 0.83–1.14,
p ¼ 0.50), respectively.14Moreover, all combinedRRsofbleed-
ing were significantly lower for patients treated with DOACs,
which is especially relevant for nonintracranial bleeding (RR:
0.39, 95% CI: 0.16–0.94) and fatal bleeding (RR: 0.36, 95% CI:
0.15–0.87). These results confirm that DOACs present lower
risk of major bleeding compared with VKAs and that DOACs
and VKAs have a similar efficacy in the treatment of acute PE.
Patients with right ventricular dysfunction were mostly
excluded from the DOACs clinical trial programs. Only the
HOKUSAI study involved a predefined subgroup analysis in
PE patients with signs of right ventricular dysfunction
defined as a concentration of NT-proBNP of 500 pg/mL or
higher or CT evidence of right ventricular dilatation.15 The
rates of recurrent VTE in the edoxaban-treated group and in
the warfarin-treated group were 2.6 and 4.6% (RR: 0.57, 95%
CI: 0.27–1.17; p ¼ 0.033), respectively. The rates of major
bleeding and the duration of heparin treatment were similar
in the edoxaban and warfarin groups (2.7 vs. 2.6%). Based on
these results, there is no reason to question the safety and
efficacy of DOACs in patients with stable PE.
Importantly, all phase 3 trial programs used comparable
exclusion criteria, including patients with cancer-associated
VTE, with high risk of bleeding, during pregnancy or breast-
feeding, and with renal insufficiency (creatinine clearance
below 30mL/minute). For that reason, DOACs cannot cur-
rently be used in these patient categories.
Long-Term Treatment after 3 Months of
Initial Anticoagulant Therapy
DOACs have been assessed on long-term secondary preven-
tion after initial management for VTE as well.6,8–11,16 The
results of these studies are summarized in ►Table 2.
Rivaroxaban was compared with placebo in 1,196 patients
for an additional 6 to 12 months in the EINSTEIN-extension
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study, and was associated with a significant lower VTE recur-
rence riskcomparedwithplacebo(1.3vs.7.1%,HR:0.18,95%CI:
0.09–0.39). Four patients in the rivaroxabangrouphadnonfatal
major bleeding (0.7%) versus none in the placebo group.6
EINSTEIN CHOICE study is a multicenter, randomized, dou-
ble-blind study comparing the efficacy and the safety of two
doses of rivaroxaban (20 and 10 mg, once daily) with aspirin
(100 mg daily) for the prevention of recurrent VTE in patients
who completed 6 to 12 months of anticoagulant therapy for
acute VTEwith intermediate risk of VTE recurrence.9 A total of
1,107 patients were treated with rivaroxaban 20 mg, 1,127
with rivaroxaban 10 mg, and 1,131 with aspirin. Symptomatic
Table 1 DOACs phase 3 trials on acute VTE treatment




















1.5 1.8 2.75 2.75 2.0 2.0
Number of patients 8,292 5,395 2,539 2,589 3,449 4,832
Number of PE
(DVT)
3,319 1,836 786 816 23 4,832
Primary efficacy
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Comparator LMWH/VKA LMWH/VKA Enox/VKA Enox/VKA Enox/VKA Enox/VKA











































matic VTE or related
death, DOACs vs.
VKA (%)
3.2 vs. 3.5a 2.3 vs. 2.7a 2.4 vs. 2.1a 2.3 vs. 2.2a 2.1 vs. 3.0a 2.1 vs. 1.8a
All-cause mortality,
DOACs vs. VKA (%)
3.2 vs. 3.1 1.5 vs. 1.9 1.6 vs. 1.7 2.0 vs. 1.9 2.2 vs. 2.9 2.4 vs. 2.1
Major bleeding,
DOACs vs. VKA (%)




8.5 vs. 10.3b 4.3 vs. 9.7b 5.6 vs. 8.8b 5.3 vs. 8.5b 8.1 vs. 8.1 10.3 vs. 11.4
Abbreviations: CRNM, clinically relevant nonmajor; DOACs, direct oral anticoagulants; DVT, deep venous thrombosis; LMWH, low-molecular-weight
heparin; PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism.
aNoninferior.
bStatistically significant difference.
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recurrent or nonfatal VTE occurred in 17 patients receiving
20 mg of rivaroxaban (1.5%), in 13 patients receiving 10 mg of
rivaroxaban (1.2%) and in 13 of 1,127 patients receiving aspirin
(4.4%; HR: 0.34, 95% CI: 0.20–0.59) for 20 mg of rivaroxaban
versus aspirin; HR: 0.26, 95% CI: (0.14–0.47) for 10 mg of
rivaroxabanversus aspirin (p < 0.001). Rates ofmajor bleeding
for the group receiving 20 mg of rivaroxaban, for the group
receiving 10 mg of rivaroxaban, and for the aspirin groupwere
0.5, 0.4, and 0.3%, respectively.
Two doses of apixaban have been compared with placebo
after 12 months of initial treatment.10 The AMPLIFY exten-
sion study included 2,486 patients with intermediate risk of
VTE recurrence and showed that both treatment doses (5 and
2.5 mg twice daily) reduced the risk of recurrent VTE com-
pared with placebo (1.7% in both groups vs. 8.8% for placebo
group). HRs for apixaban 2.5 mg group and apixaban 5 mg
group versus placebo group were 0.19 (95% CI: 0.11–0.33)
and 0.20, (95% CI: 0.11–0.34), respectively. These two doses
(2.5 and 5 mg) were not associated with a higher risk of
major bleeding compared with placebo (0.2 vs. 0.1 vs. 0.5%,
respectively). HRs for apixaban 2.5 mg group and apixaban
5 mg group versus placebo group were 0.49 (95% CI: 0.09–
2.64) and 0.25 (95% CI: 0.33–2.24), respectively.
Dabigatran has been comparedwith conventional treatment
with warfarin in RE-MEDY study and with placebo in RE-
SONATE study.8 RE-MEDY study showed that dabigatran was
noninferior in preventing recurrent VTE compared with war-
farin (1.8 vs. 1.3%, HR: 1.44, 95% CI: 0.78–2.64) with a non-
significant lower riskofmajorhemorrhage (0.9vs.1.8%,HR:0.52,
95%CI:0.27–1.02) inpatientswithhighriskofVTErecurrence. In
the placebo-control study, recurrent VTE occurred in 3 of 681
patients in the dabigatran group (0.4%) and 37 of 662 patients in
the placebo group (5.6%; HR: 0.08; 95% CI: 0.02–0.25). Major
bleedingoccurred in twopatients in the dabigatrangroup (0.3%)
and 0 patients in the placebo group. Major or clinically relevant
bleeding occurred in 36 patients in the dabigatran group (5.3%)
and 12 patients in the placebo group (1.8%; HR: 2.92; 95% CI:
1.52–5.60). Acute coronary syndromes occurred in one patient
each in the dabigatran and placebo groups.
Edoxaban has also been compared with warfarin as
extended VTE treatment in a post hoc analysis11 of the
Hokusai-VTE study.4Of the3,633patients receiving edoxaban,
1,076 (30%) received treatment between 3 and 6 months, 896
(25%)between6and less than12months, and1,661 (46%) for a
full 12 months. The cumulative incidence of recurrent VTE on
treatment (day 1 to 12 months) was 1.3% in the edoxaban
group and 1.6% in thewarfarin group (HR: 0.83; 95% CI: 0.58–
1.19). Major bleeding risk was 1.2% in the edoxaban group and
1.3% in the warfarin group (HR: 0.92; 95% CI: 0.62–1.37). A
meta-analysis including the earlier-discussed studies asses-
sing rivaroxaban, apixaban, and dabigatran as extended treat-
ment has shown that DOACs are an effective treatment for
prevention of VTE or VTE-related death in the extended
treatment setting.17
These trials showed that extended therapy using DOACs
was not inferior to warfarin or placebo in terms of efficacy.
However, they did not demonstrate that low dose of DOACs is
noninferior to full dose in termsofefficacyor superior in terms
of safety in patients with high risk of recurrence. The optimal
duration of anticoagulant treatment after the initial 3 months
should depend on the weighing of the risk for recurrent VTE
after anticoagulant therapy is stopped18–22 and the risk of
Table 2 DOACs clinical trials on extended treatment of VTE
Trial name RE-SONATE RE-MEDY EINSTEIN
extension













































Placebo Aspirin Aspirin Placebo Placebo Warfarin
(NR 2–3)














5.3 vs. 1.8 5.6 vs. 10.2 6.0 vs. 1.2 3.3 vs. 2.0 2.4 vs. 2.0 3.2 vs. 2.7 4.3 vs. 2.7 8.3 vs. 9.8
Abbreviations: CRNM, clinically relevant non major; DOACs, direct oral anticoagulants; VTE, venous thromboembolism.
aVTE-related deaths are not reported.
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anticoagulant therapy-associated hemorrhage.23,24 For
patients with PE provoked by a transient risk factor, antic-
oagulation is recommended for 3 months (recommendation
Class I, Level B) since the recurrent risk is very low,1,25,26
whereas for patientswith unprovokedPE, oral anticoagulation
is recommended for at least 3 months1,27,28 and extended
anticoagulation should be considered for patients with a first
episode of unprovoked PE (recommendation Class IIa, Level B)
due to the high risk of recurrence.1,29 Indeed, the PADIS-PE
trial, extended treatment of 2 years, comparedwith 6months,
did not reduce VTE recurrence risk after anticoagulation has
been stopped.18 Threehundred and seventy-onepatientswith
a first episode of symptomatic unprovoked PE, who had been
treated initially for 6 months with VKA, were randomized to
receive an additional 18 months of treatment with warfarin
versus additional 18 months of treatment with placebo. The
primary composite outcome of VTE recurrence or major
bleeding after 18 months after randomization occurred in 6
of 184 patients (3.3%) in the warfarin group and in 25 of 187
(13.5%) in the placebo group (HR: 0.22; 95% CI: 0.09–0.55;
p ¼ 0.001). Major bleeding occurred in four patients in the
warfarin group and in one patient in the placebo group (HR:
3.96; 95% CI: 0.44–35.89) and recurrent VTE occurred in three
patients in the warfarin group and 25 patients in the placebo
group (HR ¼ 0.15; 95% CI: 0.05–0.43). After 42 months of
follow-up, VTE recurrence was not significantly different and
the bleeding rates were similar between the two groups.
Extended anticoagulation should also be considered for
patients with PE and active cancer as well until the cancer is
cured (recommendation Class IIa, Level c).1,30–32 The ESC
guidelines published in 2014 recommended to consider dabi-
gatran, rivaroxaban, and apixaban as an alternative to VKA in
extended VTE anticoagulation,1 whereas the recent ACCP
guidelines published in 2016 recommend DOACs as long-
term anticoagulant therapy over VKA therapy (Grade B).2
How to Use DOACs?
Although effective and safe, the disadvantages of conven-
tional anticoagulant therapy with LMWH/VKAs include the
numerous interactionswith foods and drugs aswell as a need
for INR monitoring and dose adjustments.33 In routine
clinical practice, DOACs have simplified therapeuticmanage-
ment of VTE.34 Indeed, DOACs can be given in fixed doses
without routine monitoring and present minimal food and
drug interaction.35 The additional advantage of DOACs is a
similarly rapid onset of action to LMWH with oral adminis-
tration and the safety to switch from VKAs.36 Moreover,
DOACs facilitate home treatment in stable patients with PE,
reducing healthcare cost. Indeed, a new ongoing trial (Home
Treatment of Pulmonary Embolism—HoT-PE) aims to con-
firm that home treatment of acute low-risk PE with the oral
factor Xa inhibitor rivaroxaban is effective, safe, and poten-
tially cost-saving.37
Nevertheless, there are few contraindications for DOAC
initiation: (1) creatinine clearance <30mL/min, (2) moder-
ate or severe hepatic impairment (Child–Pugh B and C), or
hepatic disease associated with coagulopathy and (3) con-
comitant use of combined P-glycoprotein (amiodarone, qui-
nidine, verapamil) and strong CYP3A4 inhibitors or inducers,
and (4) and pregnancy or breastfeeding. Rivaroxaban and
apixaban should be initiated in a higher starting dose for 21
and 7 days, respectively, without the need for preceding
heparin therapy, whereas dabigatran or edoxaban is initiated
after a previous 5-day parenteral anticoagulation phase.
DOACs dosage and contraindications are summarized
in ►Table 3. Efficacy and safety seem similar between
different DOACs. DOACs have never been directly compared
in randomized studies. Hence, today, there is no evidence to
recommend one DOAC over another.38
As for DOAC reversal, several specific antidotes have been
assessed.39–44 DOACs reversal should be considered in case of
urgent surgeries associated with a high risk of bleeding or
during ongoing bleeding despite supportive measures. They
should also be considered with life-threatening bleeding in
caseof intracranial hemorrhageorwhen itoccurs into a critical
organ (e.g., intraocular bleeding), or a closed space (e.g., retro-
peritoneal or pericardial bleeding). An ongoing prospective
noninterventional registry including patients with life-threa-
tening bleeding or emergency operations either treated with
DOACs or VKAs will aim to evaluate effects of specific and
unspecific reversal agents.45 Idarucizumab is a humanized
monoclonal antibody fragment derived from an IgG1 isotype
molecule, whose target is the direct thrombin inhibitor dabi-
gatran.Andexanetalfa isa recombinantmodifiedhumanfactor
Xa decoy protein that has been shown to reverse the inhibition
of factor Xa (rivaroxaban, apixaban, edoxaban, and heparin).
Ciraparantag is a synthetic small moleculewhich binds DOACs
via hydrogen bond formation (dabigatran, rivaroxaban, apix-
aban, edoxaban, andheparin) and reverses all of theDOACsand
heparin.Most trials havebeenconducted inhealthy volunteers
and not had a comparator arm. Therefore, both reversal agents
are currently not available for clinical practice. Only idaruci-
zumab (dabigatran antidote) is licensed and widely available.
Theefficacyand the safetyof idarucizumabwasevaluated inan
analysis of 90 patients and showed that it completely reversed
the anticoagulant effect of dabigatran within minutes.39 The
phase 3,multicenter trial, assessing idarucizumab treatedwith
dabigatran in 301 patients who had uncontrolled bleeding
(GroupA)and in202patientswhorequiredemergencysurgery
(Group B), has recently been published.40 In Group A, the
median time to the cessation of bleeding was 2.5 hours,
whereas the median time to the initiation of the intended
procedure was 1.6 hours in group B. At 90 days, thrombotic
events occurred in 6.3% in group A and in 7.4% in group B. The
mortality rate was 18.8 and 18.9%, respectively. Thus, idaruci-
zumab reversed safely and rapidly the anticoagulant effect of
dabigatran. Two phase 3 trials have reported good efficacy and
good safety with andexanet alfa for reversal effect of apixaban,
rivaroxaban, edoxaban, or enoxaparin.41,42 A preliminary ana-
lysis from an ongoing prospective study (NCT02329327)
including 67 patients with acute major bleeding after the
administration of a factor Xa inhibitor showed that thrombotic
events occurred in 12 of 67 patients (18%) during the 30-day
follow-up. Clinical hemostasiswas excellent or good in37of 47
patients in the efficacy analysis (79%; 95% CI: 64–89) 12 hours
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after the andexanet alfa infusion.41 Ciraparantag has been
assessed in a double-blind phase 2, placebo-controlled trial
among 80 healthy adult patients. The results showed an
immediate and sustained full reversal of edoxaban.43 Similar
results have been reported for enoxaparin.44
Real-Life Registries
Real-world studies with DOACs including unselected patients
with DVT and PE are of particular interest to support and to
evaluate the reproducibility of the phase 3 trial findings. We
will discuss the largest studies published to date.46–50 The
results of these noninterventional studies are summarized
in ►Table 4.
XALIA study is a multicenter, prospective, noninter-
ventional study, including 2,619 patients treated with
rivaroxaban and 2,149 patients treated with standard anti-
coagulation therapy.47 All included patients diagnosed with
DVT had an indication to be treated for at least 3 months.
Patients with isolated PE were excluded. The rate of major
bleeding was 0.8% (19/2505) in the rivaroxaban group and
2.1% (43/2,010) in the standard anticoagulation group (HR:
0.77, 95% CI: 0.40–1.50; p ¼ 0.44). The rates of frequency of
recurrent VTE in the rivaroxaban and standard anticoagula-
tion groupwere 1.4% (36/2,505) and 2.3% (47/2,010), respec-
tively (HR: 0.91, 95% CI: 0.54–1.54, p ¼ 0.72). The rate of all-
cause mortality was 0.4% (11/2,505) in the rivaroxaban
group and 3.4% (69/2,010) in the standard anticoagulation
group (HR: 0.51; 95% CI: 0.24–1.07). The rate of fatal PE was
<0.1% in both groups.
The DRESDEN study included 1,776 patientswith DVT, PE,
or atrial fibrillation (AF) treated with rivaroxaban in routine
practice.48 The rates of major bleeding (4.1%) and mortality
(6.3%) were higher than recorded in XALIA study. The main
reasons of this difference are the older age and the higher
proportion of patients with renal impairment in the DRES-
DEN registry. Despite the lack of comparator group treated
with VKA, bleeding rates with rivaroxaban were lower and
the outcome of major bleeding at 90 days is better than that
reported for VKA.
The REMOTEVcohort included 499 patients with DVT and
PE.49 The rates of major bleeding, and recurrent DVT with
rivaroxaban were coherent with those reported in XALIA
registry, 1.4 versus 3.1%, respectively. The frequency ofmajor
bleeding was 1.1% in rivaroxaban group versus 3.1% in the
warfarin group.
PREFER VTE registry is a large international, noninterven-
tional database including 3,455 patients with PE and DVT,
Table 3 DOACs doses and contraindications
Direct oral
anticoagulant
Initial dose Standard dose Contraindications
Edoxaban At least 5 d combined with par-
enteral anticoagulation
60 mg once daily
30 mg once daily can be consid-
ered in patients with one ormore
of the following factors: CrCl 30–
49mL/min; body weight60 kg;




Moderate or severe hepatic
impairment (Child–Pugh B and





Apixaban First 7 d, 10 mg twice daily 5 mg twice daily CrCl <15 mL/min
Severehepatic impairment (Child–
Pugh C) or hepatic disease asso-
ciated with coagulopathy
Strong dual inhibitors or inducers
of CYP3A4 and P-gp
Pregnancy and breastfeedinga
Dabigatran At least 5 d with parenteral
anticoagulation
150 mg twice daily




P-gp inhibitorsa in patients with
CrCl <50 mL/min
Concomitant treatment with
P-gp inducers (i.e., rifampicin)
Pregnancy and breastfeedinga
Rivaroxaban First 3 wk 15 mg twice daily 20 mg once daily
15 mg once daily if CrCl 30–49
mL/min
CrCl <30 mL/min
Moderate or severe hepatic
impairment (Child–Pugh B and
C), or hepatic disease associated
with coagulopathy
Concomitant use of combined
P-gp and strong CYP3A4 inhibi-
tors or inducers
Pregnancy and breastfeedinga
aNo assessment during pregnancy and breastfeeding.
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one quarter of who received DOACs.50 This study did not
compare patients according DOACs versus standard antic-
oagulation, but according VTE presentation (DVT vs. PE vs.
DVT  PE). The rate of major bleeding was not higher than
reported in other registries (1.5%, 33/2,326). The high rate of
mortality (6.7%, 230/3,455) could be explained by the high
proportion of patients with active cancer (8.5%).
The Global Anticoagulant Registry in the FIELD-Venous
Thromboembolism (GARFIELD-VTE) is a prospective, multi-
center, observational study that will enroll 10,329 patients
treated for acute VTE in 28 countries.46 Patients included in
GARFIELD-VTE have been treated with DOACs in 50.5% of
cases. The incidence of all causes of death, recurrent VTE, and
major bleeding of the overall cohort after 6months of follow-
up were 11.1, 3.6, and 2.8%, respectively.
Thus, real-world registries have shown consistently that
the rate of major bleeding and recurrent VTE under DOAC
therapy is low. These data reinforce the findings of the phase
3 studies that DOACs are efficient and safe in the therapeutic
management of acute VTE.
Conclusion
Phase 3 trials have shown that DOACs have comparable
efficacy but a better safety profile than conventional antic-
oagulant treatment with LMWH and VKA in patients with
acute VTE. Moreover, DOACs are effective and safe for the
extended treatmentofVTE aswell. Results of real-word cohort
studies andregistrieshave confirmed the results of thephase3
trials, supporting the guideline recommendations that acute
VTE should be preferably treated with DOACs, except for
patients with cancer-associated VTE, high risk of bleeding,
during pregnancy or breast feeding, and severe renal insuffi-
ciency (creatinine clearance <30mL/min).
Table 4 DOACs real-world studies
Registry name XALIA DRESDEN REMOTEV PREFER GARFIELDa
DOACs Rivaroxaban Rivaroxaban Rivaroxaban DOACsb DOACsc
























Population DVT DVT, EP, AF DVT, EP DVT, EP DVT, EP





6 vs. 19% NP 2.6 vs. 8.1% 8.5%d 9.1%
Follow-up > 12 mo 3 mo 6 mo 12 mo 3 y
Comparator Standard anticoa-
gulation therapye
No comparator Standard anticoa-
gulation therapyf












0.4 vs. 3.4% 6.3%h 1.8 vs. 5.2% 6.7%d 11.1%g
Abbreviations: AF, atrial fibrillation; DOACs, direct oral anticoagulants; DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; NP, not
provided; PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism.
aGARFIELD VTE study results are not yet published. They are extracted from ISTH Congress abstract.
bType of DOACs not provided.
cIn GARFIELD registry, 50.5% of patients are treated with DOACs.
dNo distinction between DOACS and standard anticoagulation therapy.
eUnfractioned heparin–LMWH or fondaparinux followed by VKAs.
fMajor bleeding rate in VTE population.
gNo distinction provided in the abstract between DOACS and other treatment.
hNo distinction between AF and VTE population.
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